COMPANY
MitoChem Therapeutics
NIH awards 2
- NIH award 1R43EY037591-01A1 FY2026: $320,790 awarded for that fiscal year; activity R43 (SBIR); PI VOEVODSKY, MICHAEL; recipient as written: MITOCHEM THERAPEUTICS INC., CHARLESTON, SC. Novel gene mutation agnostic sm source ↗
- NIH award 1R43EY021983-01 FY2012: $233,491 awarded for that fiscal year; activity R43 (SBIR); PI LINDSEY, CHRIS; recipient as written: MITOCHEM THERAPEUTICS, LLC, CHARLESTON, SC. Neuroprotective agents for retinal di source ↗
Funding and NIH signals
- NIH award NIH awarded $321K (SBIR Phase I 1R43EY037591-01A1, new, notice Sep 17, 2026). NIH RePORTER 1R43EY037591-01A1 (Sep 17, 2026)
Evidence (1 event)
- Sep 17, 2026 · NIH RePORTER 1R43EY037591-01A1
Organization: MITOCHEM THERAPEUTICS INC.; City/State: CHARLESTON, SC; Project number: 1R43EY037591-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 320790; Administering IC: National Eye Institute; Project title: Novel gene mutation agnostic small molecule to treat retinitis pigmentosa; Organization type: Domestic For-Profits
- Sep 17, 2026 · NIH RePORTER 1R43EY037591-01A1